Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
August 21, 2026
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
August 4, 2026
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 14, 2026
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
May 6, 2026
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
March 31, 2026
1
2
Next Page
→